ZURICH/BERLIN, June 16 (Reuters) - Here are some of the
main factors that may affect Swiss stocks on Friday:
Roche ROG.S : the U.S. Food and Drug Administration has
approved the antibody Columvi by subsidiary Genentech, which
will become available in the United States in the coming weeks.
Interroll INRN.S expects lower sales and operating profit.
European refiner and trader Varo Energy is acquiring biogas
supplier Renewable Energy Services (RES), its second deal this
year in a sector which is expected to grow rapidly as economies
seek to reduce carbon emissions.
Ukrainian President Volodymyr Zelenskiy on Thursday urged
Switzerland to allow the re-export of weapons to Ukraine, saying
the move would be vital in defeating Russia's invasion.
ECONOMY
No major Swiss economic data scheduled.
(Reporting by Zurich newsroom and Berlin Speed Desk)
((+41 58 306 7336; zurich.newsroom@thomsonreuters.com))
((For Top News in a multimedia Web format on Eikon visit: https://bit.ly/2NDFd6g
FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
Daily Swiss stock market report in German .SDE
All SMI constituent stocks 0#.SSMI
DJ STOXX index .STOXX
Top 10 STOXX sectors .PGL.STOXXS
Top 10 EUROSTOXX sectors .PGL.STOXXES
Swiss mid-cap index .SSMI
Swiss all-share index .SSHI
Swiss market digest .AD.S
Sector overview CH/SECTOR1
All Swiss news CH
Swiss research news CH-RCH
All equity news E
SPEED GUIDES: EQUITY EQUITY/NEWS1 EUR/EQUITY SWITZERLAND REUTERS ))